Vanda Pharmaceuticals. has filed a patent for the use of R-P88 in treating psychiatric disorders with atypical antipsychotic properties. The method involves administering R-P88 once a day to patients. GlobalData’s report on Vanda Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Vanda Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Vanda Pharmaceuticals, Peptide pharmacophores was a key innovation area identified from patents. Vanda Pharmaceuticals's grant share as of January 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.

A newly filed patent (Publication Number: US20240016791A1) discloses a method for treating patients with psychiatric disorders using R-P88, a pharmaceutical compound. The method involves internally administering R-P88 or its derivatives once or twice a day, without the need for titration. The disorders that can be treated include schizophrenia, bipolar disorder, depression, autism, and others. The dosage ranges from 1 to 24 mg per day, depending on the specific condition being treated. The patent also covers pharmaceutical compositions containing R-P88 and a carrier, formulated for once or twice daily administration.

The patent claims highlight the potential use of R-P88 in treating a range of psychiatric disorders, offering a novel approach to patient care. By providing specific dosing guidelines and formulations for administration, the patent aims to optimize the therapeutic benefits of R-P88 while simplifying the treatment process for healthcare providers and patients. The inclusion of different dosage options and administration frequencies allows for flexibility in tailoring the treatment to individual patient needs. Overall, the patent presents a promising avenue for the development of new treatment options in the field of psychiatric medicine.

To know more about GlobalData’s detailed insights on Vanda Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies